481 related articles for article (PubMed ID: 16354907)
1. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.
Deane R; Sagare A; Hamm K; Parisi M; LaRue B; Guo H; Wu Z; Holtzman DM; Zlokovic BV
J Neurosci; 2005 Dec; 25(50):11495-503. PubMed ID: 16354907
[TBL] [Abstract][Full Text] [Related]
2. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.
Deane R; Bell RD; Sagare A; Zlokovic BV
CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):16-30. PubMed ID: 19275634
[TBL] [Abstract][Full Text] [Related]
3. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.
Shackleton B; Crawford F; Bachmeier C
Fluids Barriers CNS; 2016 Aug; 13(1):14. PubMed ID: 27503326
[TBL] [Abstract][Full Text] [Related]
5. Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.
Qosa H; Abuasal BS; Romero IA; Weksler B; Couraud PO; Keller JN; Kaddoumi A
Neuropharmacology; 2014 Apr; 79():668-78. PubMed ID: 24467845
[TBL] [Abstract][Full Text] [Related]
6. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.
Bell RD; Sagare AP; Friedman AE; Bedi GS; Holtzman DM; Deane R; Zlokovic BV
J Cereb Blood Flow Metab; 2007 May; 27(5):909-18. PubMed ID: 17077814
[TBL] [Abstract][Full Text] [Related]
7. Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q; Zhao Z; Sagare AP; Wu Y; Wang M; Owens NC; Verghese PB; Herz J; Holtzman DM; Zlokovic BV
Mol Neurodegener; 2018 Oct; 13(1):57. PubMed ID: 30340601
[TBL] [Abstract][Full Text] [Related]
8. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
9. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
10. LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier.
Pflanzner T; Janko MC; André-Dohmen B; Reuss S; Weggen S; Roebroek AJ; Kuhlmann CR; Pietrzik CU
Neurobiol Aging; 2011 Dec; 32(12):2323.e1-11. PubMed ID: 20630619
[TBL] [Abstract][Full Text] [Related]
11. The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.
Storck SE; Hartz AMS; Bernard J; Wolf A; Kachlmeier A; Mahringer A; Weggen S; Pahnke J; Pietrzik CU
Brain Behav Immun; 2018 Oct; 73():21-33. PubMed ID: 30041013
[TBL] [Abstract][Full Text] [Related]
12. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Pardridge WM
Bioconjug Chem; 2007; 18(2):447-55. PubMed ID: 17315944
[TBL] [Abstract][Full Text] [Related]
13. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier.
Bachmeier C; Beaulieu-Abdelahad D; Mullan M; Paris D
Eur J Pharmacol; 2011 Jun; 659(2-3):124-9. PubMed ID: 21497592
[TBL] [Abstract][Full Text] [Related]
14. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.
Deane R; Wu Z; Sagare A; Davis J; Du Yan S; Hamm K; Xu F; Parisi M; LaRue B; Hu HW; Spijkers P; Guo H; Song X; Lenting PJ; Van Nostrand WE; Zlokovic BV
Neuron; 2004 Aug; 43(3):333-44. PubMed ID: 15294142
[TBL] [Abstract][Full Text] [Related]
15. Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer's disease.
Elmer BM; Swanson KA; Bangari DS; Piepenhagen PA; Roberts E; Taksir T; Guo L; Obinu MC; Barneoud P; Ryan S; Zhang B; Pradier L; Yang ZY; Nabel GJ
PLoS One; 2019; 14(12):e0226245. PubMed ID: 31887144
[TBL] [Abstract][Full Text] [Related]
16. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.
Shibata M; Yamada S; Kumar SR; Calero M; Bading J; Frangione B; Holtzman DM; Miller CA; Strickland DK; Ghiso J; Zlokovic BV
J Clin Invest; 2000 Dec; 106(12):1489-99. PubMed ID: 11120756
[TBL] [Abstract][Full Text] [Related]
17. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.
Deane R; Singh I; Sagare AP; Bell RD; Ross NT; LaRue B; Love R; Perry S; Paquette N; Deane RJ; Thiyagarajan M; Zarcone T; Fritz G; Friedman AE; Miller BL; Zlokovic BV
J Clin Invest; 2012 Apr; 122(4):1377-92. PubMed ID: 22406537
[TBL] [Abstract][Full Text] [Related]
18. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier.
Zhou AL; Swaminathan SK; Salian VS; Wang L; Curran GL; Min HK; Lowe VJ; Kandimalla KK
Mol Pharm; 2024 May; 21(5):2176-2186. PubMed ID: 38625027
[TBL] [Abstract][Full Text] [Related]
19. Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease.
Nishida Y; Ito S; Ohtsuki S; Yamamoto N; Takahashi T; Iwata N; Jishage K; Yamada H; Sasaguri H; Yokota S; Piao W; Tomimitsu H; Saido TC; Yanagisawa K; Terasaki T; Mizusawa H; Yokota T
J Biol Chem; 2009 Nov; 284(48):33400-8. PubMed ID: 19679659
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy.
Gustafsson S; Gustavsson T; Roshanbin S; Hultqvist G; Hammarlund-Udenaes M; Sehlin D; Syvänen S
Neuropharmacology; 2018 Dec; 143():1-9. PubMed ID: 30201212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
